A number of expert committees are currently reviewing the provision of plasma components in the UK - whilst this review is in progress, this 2004 guideline (plus 2005, 2007 and 2016 addendum remain current BSH guidance.
(Please see the 2005 amendment (selection according to RhD and ABO group), 2007 amendment (storage of cryoprecipitate) and the 2016 amendment to the guidelines for use of fresh frozen plasma, cryoprecipitate and cryosupernatant).
Please see the 2011 guideline on Warfarin for guidance on the reversal of warfarin (a Haemotstasis and Thrombosis guideline).
This guideline has an update please see the information below.
Declaration of Interests
The BSH paid the expenses incurred during the writing of this guidance. None of the authors had conflicts of interest to declare. All authors have made a declaration of interests to the BSH and Task Force Chairs which may be viewed on request.